10 20 30 40 50 60 70 80 1ND8 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER SIGNALING PROTEIN 09-DEC-02 1ND8
TITLE THEORETICAL MODEL OF HUMAN CCR5 WITH DISULFIDE BOND BETWEEN TITLE 2 CYS20 AND CYS269
COMPND MOL_ID: 1; COMPND 2 MOLECULE: C-C CHEMOKINE RECEPTOR TYPE 5; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CCR5, C-C CKR-5, CC-CKR-5, CCR-5
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN
KEYWDS A BUNDLE OF SEVEN TRANSMEMBRANE ALPHA HELICES
EXPDTA THEORETICAL MODEL
AUTHOR S.Q.LIU,X.F.SHI,Z.R.SUN
REVDAT 1 30-DEC-02 1ND8 0
JRNL AUTH S.Q.LIU,X.F.SHI,Z.R.SUN JRNL TITL CHARACTERIZE DYNAMIC CONFORMATIONAL SPACE OF HUMAN JRNL TITL 2 CCR5 EXTRACELLULAR DOMAIN BY MOLECULAR MODELING JRNL TITL 3 AND MOLECULAR DYNAMICS SIMULATION JRNL REF TO BE PUBLISHED JRNL REFN
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : INSIGHT II REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 1ND8 COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 11-DEC-2002. REMARK 100 THE RCSB ID CODE IS RCSB017778.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: THIS STRUCTURE WAS BUILT USING HOMOLOGY MODELING REMARK 220 METHOD. THE SEVEN TRANSMEMBRANE HELICES WAS FIX DURING REMARK 220 MOLECULAR DYNAMICS. THE N-TERMINUS 1-19 REGION OF THIS REMARK 220 STRUCTURE EXTENDS INTO THE OUTER SPACE OF THE DOMAIN REMARK 220 FORMED BY EXTRACELLULAR LOOP1-3
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 16 130.52 71.15 REMARK 500 TYR A 176 -58.79 68.11 REMARK 500 TRP A 190 -59.10 70.54 REMARK 500 VAL A 199 -56.08 74.27 REMARK 500 ARG A 225 -75.47 73.43 REMARK 500 ASN A 226 -53.62 78.70 REMARK 500 ARG A 235 -62.14 74.32 REMARK 500 PHE A 260 -41.16 70.07 REMARK 500 GLN A 261 -70.48 83.79 REMARK 500 CYS A 269 -102.43 60.48 REMARK 500 TYR A 307 -82.85 75.93 REMARK 500 GLN A 328 -92.88 64.37 REMARK 500 SER A 336 -105.45 60.34 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 LEU A 207 LEU A 208 -148.33
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1F88 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF RHODOPSIN:A G PROTEINCCOUPLED REMARK 900 RECEPTOR, WHICH IS SELECTED AS THE TEMPLATE IN BUILDING THE REMARK 900 TRANSMEMBRANE REGIONS OF CCR5 MODEL. REMARK 900 RELATED ID: 1NE0 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF HUMAN CCR5 WITH DISULFIDE BOND BETWEEN REMARK 900 CYS20 AND CYS269
DBREF 1ND8 A 1 352 UNP P51681 CKR5_HUMAN 1 352
SEQRES 1 A 352 MET ASP TYR GLN VAL SER SER PRO ILE TYR ASP ILE ASN SEQRES 2 A 352 TYR TYR THR SER GLU PRO CYS GLN LYS ILE ASN VAL LYS SEQRES 3 A 352 GLN ILE ALA ALA ARG LEU LEU PRO PRO LEU TYR SER LEU SEQRES 4 A 352 VAL PHE ILE PHE GLY PHE VAL GLY ASN MET LEU VAL ILE SEQRES 5 A 352 LEU ILE LEU ILE ASN CYS LYS ARG LEU LYS SER MET THR SEQRES 6 A 352 ASP ILE TYR LEU LEU ASN LEU ALA ILE SER ASP LEU PHE SEQRES 7 A 352 PHE LEU LEU THR VAL PRO PHE TRP ALA HIS TYR ALA ALA SEQRES 8 A 352 ALA GLN TRP ASP PHE GLY ASN THR MET CYS GLN LEU LEU SEQRES 9 A 352 THR GLY LEU TYR PHE ILE GLY PHE PHE SER GLY ILE PHE SEQRES 10 A 352 PHE ILE ILE LEU LEU THR ILE ASP ARG TYR LEU ALA VAL SEQRES 11 A 352 VAL HIS ALA VAL PHE ALA LEU LYS ALA ARG THR VAL THR SEQRES 12 A 352 PHE GLY VAL VAL THR SER VAL ILE THR TRP VAL VAL ALA SEQRES 13 A 352 VAL PHE ALA SER LEU PRO GLY ILE ILE PHE THR ARG SER SEQRES 14 A 352 GLN LYS GLU GLY LEU HIS TYR THR CYS SER SER HIS PHE SEQRES 15 A 352 PRO TYR SER GLN TYR GLN PHE TRP LYS ASN PHE GLN THR SEQRES 16 A 352 LEU LYS ILE VAL ILE LEU GLY LEU VAL LEU PRO LEU LEU SEQRES 17 A 352 VAL MET VAL ILE CYS TYR SER GLY ILE LEU LYS THR LEU SEQRES 18 A 352 LEU ARG CYS ARG ASN GLU LYS LYS ARG HIS ARG ALA VAL SEQRES 19 A 352 ARG LEU ILE PHE THR ILE MET ILE VAL TYR PHE LEU PHE SEQRES 20 A 352 TRP ALA PRO TYR ASN ILE VAL LEU LEU LEU ASN THR PHE SEQRES 21 A 352 GLN GLU PHE PHE GLY LEU ASN ASN CYS SER SER SER ASN SEQRES 22 A 352 ARG LEU ASP GLN ALA MET GLN VAL THR GLU THR LEU GLY SEQRES 23 A 352 MET THR HIS CYS CYS ILE ASN PRO ILE ILE TYR ALA PHE SEQRES 24 A 352 VAL GLY GLU LYS PHE ARG ASN TYR LEU LEU VAL PHE PHE SEQRES 25 A 352 GLN LYS HIS ILE ALA LYS ARG PHE CYS LYS CYS CYS SER SEQRES 26 A 352 ILE PHE GLN GLN GLU ALA PRO GLU ARG ALA SER SER VAL SEQRES 27 A 352 TYR THR ARG SER THR GLY GLU GLN GLU ILE SER VAL GLY SEQRES 28 A 352 LEU
HELIX 1 1 LEU A 32 LYS A 59 1 28 HELIX 2 2 TYR A 68 VAL A 83 1 16 HELIX 3 3 VAL A 83 ALA A 90 1 8 HELIX 4 4 LEU A 104 ILE A 124 1 21 HELIX 5 5 VAL A 150 PHE A 158 1 9 HELIX 6 6 LEU A 161 ILE A 165 5 5 HELIX 7 7 VAL A 199 LEU A 205 1 7 HELIX 8 8 LEU A 207 ILE A 217 1 11 HELIX 9 9 ARG A 235 PHE A 260 1 26 HELIX 10 10 ALA A 278 MET A 287 1 10 HELIX 11 11 THR A 288 ALA A 298 1 11
SSBOND 1 CYS A 20 CYS A 269 SSBOND 2 CYS A 101 CYS A 178
CISPEP 1 ASP A 2 TYR A 3 0 -0.63 CISPEP 2 SER A 17 GLU A 18 0 -12.66 CISPEP 3 PRO A 19 CYS A 20 0 14.42 CISPEP 4 ALA A 92 GLN A 93 0 5.62 CISPEP 5 GLN A 93 TRP A 94 0 -15.73 CISPEP 6 THR A 99 MET A 100 0 0.38 CISPEP 7 CYS A 101 GLN A 102 0 -7.79 CISPEP 8 TYR A 127 LEU A 128 0 -1.70 CISPEP 9 ALA A 129 VAL A 130 0 -8.35 CISPEP 10 PHE A 144 GLY A 145 0 0.38 CISPEP 11 PHE A 166 THR A 167 0 -7.22 CISPEP 12 SER A 169 GLN A 170 0 -11.55 CISPEP 13 GLN A 186 TYR A 187 0 -5.69 CISPEP 14 ARG A 223 CYS A 224 0 -25.77 CISPEP 15 ASN A 268 CYS A 269 0 -17.83 CISPEP 16 SER A 270 SER A 271 0 4.90 CISPEP 17 LEU A 275 ASP A 276 0 9.25 CISPEP 18 GLY A 301 GLU A 302 0 1.54 CISPEP 19 ALA A 317 LYS A 318 0 -7.67 CISPEP 20 ALA A 331 PRO A 332 0 8.77 CISPEP 21 VAL A 338 TYR A 339 0 -6.40 CISPEP 22 VAL A 350 GLY A 351 0 6.22
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000